Navigation Links
Keryx Biopharmaceuticals, Inc. Requests an Appeal Hearing After Receiving Notice of Delisting From Nasdaq
Date:3/9/2009

ompany's common stock.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease. The Company is also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types. The Company also has an in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: There can be no assurance that the Company will satisfy Nasdaq's conditions for continued listing on The Nasdaq Capital Market, that any potential appeal or hearing for a stay of delisting from The Nasdaq Capital Market will be successful, or that the Company
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
3. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results
4. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2008 Financial Results on Tuesday, November 11, at 8:30 A.M. EST
5. Keryx Biopharmaceuticals KRX-0401 (Perifosine) Data Selected for Oral Presentation at the 50th Annual Meeting of the American Society of Hematology
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2008 Financial Results
7. Keryx Biopharmaceuticals Receives Nasdaq Notification
8. Johnson & Johnson Completes Tender Offer for Omrix Biopharmaceuticals, Inc.
9. FDA Struggles to Keep Pace With Requests for Generics
10. President Bush Requests Funding Cuts That Endanger Domestic Violence Victims
11. Maryland Stem Cell Commission Issues Requests for Applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... September 19, 2014 Outsourcing services provider Profit ... large US IT conglomerate to provide HR outsourcing services in ... as an exclusive partner and will act as a talent ... will deploy over 120 personnel across 3 locations in India ... statement. , "This is a significant win for us and ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 Dr. John ... Therapeutic Periodontal Treatment to their Miami practice. Routinely ... Gallardo and Dr. Lamas are one of the ... ‘total health’ approach for diagnosing and treating periodontal disease. ... the most under-diagnosed and under-treated diseases in the world. ...
(Date:9/19/2014)... Dennis Thompson HealthDay Reporter ... President Barack Obama escalated the fight against antibiotic-resistant bacteria ... national strategy to deal with the threat. ... cabinet-level task force charged with crafting a national action ... ordinary and previously treatable bacteria that have become resistant ...
(Date:9/19/2014)... Chino Hills, CA (PRWEB) September 19, 2014 ... the fastest-selling fitness boot camp in the country. He’s also ... mentoring thousands of clients, coaching celebrity trainers and serving as ... He knows marketing, and he says that becoming an integral ... camp’s success. , “One of the things that Fit Body ...
(Date:9/19/2014)... DC (PRWEB) September 19, 2014 Atlantic ... and the authoritative AIS’s Directory of Health Plans — ... Facts, Trends and Data: 2014-2015. The latest edition of ... are re-shaping the health care industry. , With ... plan issues — from benefit design and management strategies ...
Breaking Medicine News(10 mins):Health News:Profit By RPO Bags huge RPO contract from US-based Implementation Partner 2Health News:Gallardo & Lamas Periodontics & Implant Dentistry Therapeutic Periodontal Treatment Shown to Improve Patient’s Overall Health 2Health News:Gallardo & Lamas Periodontics & Implant Dentistry Therapeutic Periodontal Treatment Shown to Improve Patient’s Overall Health 3Health News:Obama Calls for National Plan to Fight Antibiotic Resistance 2Health News:New Post from Boot Camp Marketing Expert Bedros Keuilian Explains Importance of Becoming Part of the Community 2Health News:New Post from Boot Camp Marketing Expert Bedros Keuilian Explains Importance of Becoming Part of the Community 3Health News:New Book from Atlantic Information Provides Insights Into Trends in the Health Care Industry 2
... but along with her, her families too have to face the ... breast has taken its toll on Ellen who is finding it ... Her family could seem to do nothing to ease the pain. ... palliative care team at Dartmouth Hitchcock Medical Center. ,A doctor ...
... they get married is a waste of breath, a US ... Sydney. // ,William Smith, the vice president of the ... that a six-year study commissioned by the US Congress found ... spent on pushing sexual abstinence outside marriage had had no ...
... only getting closer for the Bush administration and therefore many ... the one cited by the American Civil Liberties Union; they ... the federally sponsored ‘Abstinence Only Sex Education’ programme. ,The ... document compiled by Dr. John Santelli, a pediatrician at the ...
... A mental fog referred to as ‘chemo brain’ that ... it deserves. // , Patients especially women have ... as short-term memory loss, an inability to concentrate, difficulty ... that they had lost their mental edge. Once brushing ...
... found a breakthrough method of blood test to diagnose Parkinson ... blood much before the symptoms arrive. The test is done ... Institute and Melbourne University specialists. ,They have also ... application as it can screen many types of PD and ...
... interfere with the therapeutic effects of chemotherapy agents, ... use of antioxidants during chemotherapy. In fact, they ... the patient’s ability to tolerate treatment. This conclusion ... the use of antioxidant supplements during treatment. Until ...
Cached Medicine News:Health News:The Pain Relieved With the Help of Palliative Workers 2Health News:Chemo Brain- Nothing Forgettable About It 2Health News:Chemo Brain- Nothing Forgettable About It 3Health News:New Blood Test to Diagnose Parkinson Disease 2Health News:Antioxidants May Aid Chemotherapy Patients 2
(Date:9/19/2014)... Mich. , Sept. 19, 2014  Diplomat, the ... of David Dreyer to the Board of ... independent director and will also serve as chair of ... almost 30 years of accounting, financial, compliance and operating ... Mr. Dreyer has served as chief financial officer, chief ...
(Date:9/19/2014)... , Sept. 19, 2014 UBM Medica ... a leading online community to help oncologists and other ... available regarding the use of targeted therapies and immunotherapies, ... research and treatment.  Every September, ... way to raise awareness about blood cancers—helping to increase ...
(Date:9/19/2014)... 2014 Five MinuteClinic walk-in medical clinics are opening inside ... area. Three clinics opened in Memphis and ... will be added in Springfield on September ... is expected to open October 22.  MinuteClinic is the largest and ... United States . The Memphis ...
Breaking Medicine Technology:David Dreyer Appointed to Diplomat Board of Directors 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4MinuteClinic Walk-in Medical Clinics Opening in Memphis 2MinuteClinic Walk-in Medical Clinics Opening in Memphis 3
... , , , , , , , , , ... and LAUSANNE, Switzerland , February 4 ... Debiopharm Group (Debiopharm), a Swiss-based global,biopharmaceutical group of companies with ... medical needs, announce the launch by,Ipsen in France ...
... , REDWOOD CITY, Calif. , Feb. ... financial results for the year ended December 31, 2009 , which ... cash flow positive. , Total revenue for the fourth quarter of 2009 ... in the fourth quarter of 2008.  Product revenue from the Onco type ...
Cached Medicine Technology:Launch of Ipsen's Decapeptyl(R) 6-Month Formulation (LP 22.5 mg) in France for the Treatment of Locally Advanced or Metastatic Hormone-Dependent Prostate Cancer 2Launch of Ipsen's Decapeptyl(R) 6-Month Formulation (LP 22.5 mg) in France for the Treatment of Locally Advanced or Metastatic Hormone-Dependent Prostate Cancer 3Launch of Ipsen's Decapeptyl(R) 6-Month Formulation (LP 22.5 mg) in France for the Treatment of Locally Advanced or Metastatic Hormone-Dependent Prostate Cancer 4Launch of Ipsen's Decapeptyl(R) 6-Month Formulation (LP 22.5 mg) in France for the Treatment of Locally Advanced or Metastatic Hormone-Dependent Prostate Cancer 5Launch of Ipsen's Decapeptyl(R) 6-Month Formulation (LP 22.5 mg) in France for the Treatment of Locally Advanced or Metastatic Hormone-Dependent Prostate Cancer 6Genomic Health Announces Year-End 2009 Financial Results 2Genomic Health Announces Year-End 2009 Financial Results 3Genomic Health Announces Year-End 2009 Financial Results 4Genomic Health Announces Year-End 2009 Financial Results 5Genomic Health Announces Year-End 2009 Financial Results 6Genomic Health Announces Year-End 2009 Financial Results 7Genomic Health Announces Year-End 2009 Financial Results 8Genomic Health Announces Year-End 2009 Financial Results 9Genomic Health Announces Year-End 2009 Financial Results 10Genomic Health Announces Year-End 2009 Financial Results 11Genomic Health Announces Year-End 2009 Financial Results 12
Adjustable lid speculum angled 45 degrees with 17 mm curved solid blades and aspiration ports to remove excess fluid from around the eye during ocular procedures....
Open 11 mm blades. Dull finish. Most popular size or model....
Open 15 mm blades with lifting wings manipulation of I/A cannulas, knives, instrumentation, etc. Screwlocking mechanism. Dull finish....
Angled for temporal approach. Solid 14 mm blades. Dull finish....
Medicine Products: